Prognostic value of CD146 in solid tumor: A Systematic Review and Meta-analysis

Abstract

CD146, also known as melanoma cell adhesion molecule, was initially identified as a marker of melanoma progression and metastasis. Recently many clinical studies investigated overexpression of CD146 predict poor prognosis of solid tumor, however, the results was inconclusive, partly due to small numbers of patients included. This present meta-analysis was therefore performed utilizing the results of all clinical studies concerned to determine the prognostic value of CD146 expression in solid tumors. Relevant articles were identified through searching the PubMed, Web of Science and Embase database. In this meta-analysis, 12 studies involving 2,694 participants were included, and we drew the conclusion that strong significant associations between CD146 expression and all endpoints: overall survival (OS) [hazard ratio (HR) = 2.496, 95% confidence interval (95% CI) 2.115–2.946], time to progression (TTP) (HR = 2.445, 95% CI 1.975–3.027). Furthermore, the subgroup analysis revealed that the associations between CD146 overexpression and the outcome endpoints (OS or TTP) were significant in Mongoloid patients and Caucasian patients, as well in patients with lung cancer and digestive system cancer. In conclusion, these results showed that high CD146 was associated with poor survival in human solid tumors. CD146 may be a valuable prognosis predictive biomarker; nevertheless, whether CD146 could be a potential therapeutic target in human solid tumors needs to be further studied.

METCAM/MUC18: A Novel Tumor Suppressor for Some Cancers

“…In contrast to the above functions of METCAM/MUC18, recent work done on other solid tumors appears to be consistent with the meta-analysis results of solid tumors [53], as described next. For example, METCAM/MUC18 expression correlates with the epithelial-mesenchymal transition (EMT) markers and a poor prognosis in gastric cancer [57].…”

“…However, its role in the development of most of these cancers is not well known. Recent meta-analysis suggests that high METCAM/MUC18 expression in many solid tumors appears to be associated with poor prognosis and patient survival [53]. However, in contrast to the conclusion, reduced expression of METCAM/MUC18 associates with the malignant progression of hemangioma [46].…”

“…Recently, more groups have participated in further exploring the possible role of METCAM/MUC18 in other solid tumors in different organs, such as colorectum [54], gastro-organ [57], glioma [58], liver [59,60], lung [61][62][63][64][65][66], pancreas [55,56,70], and bone [67][68][69]. Preliminary work in leiomyosarcoma, esophagus squamous cell carcinoma, clear cell renal sarcoma, and gallbladder adenocarcinoma are also beginning to emerge [53].…”

Prognostic value of twist-1, e-cadherin and ezh2 in prostate cancer: an immunohistochemical study

“…Previous studies have reported that the highest expression of twist-1 was associated with high grade, invasion, metastases, and therefore unfavorable prognosis in different cancers as thyroid (28), and lung carcinomas (29). these results regarding twist-1 may help to find a new therapeutic target to inhibit the invasion, progression, and metastases in PC.…”

Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review

“…CD146 is a transmembrane glycoprotein belonging to the immunoglobulin superfamily; its increased expression is closely associated with an advanced stage of malignant melanoma, prostate and ovarian cancers (14). CD146 was tested on smear specimens of PEs from MPM and MH patients.…”